Challenges in HIV Management: Enhancing the Quality of Life for Elderly PLWH, Policy Interventions are Imperative

Challenges in HIV Management: Enhancing the Quality of Life for Elderly PLWH, Policy Interventions are Imperative

2024.01.14
IAS current President Sharon Lewin emphasized, "The past 40 years of HIV research tells us that our HIV prevention and treatment work will be effective only when science, policy, and activism come together." At this IAS conference, the concept of primary healthcare (PHC) for HIV, as highlighted in the World Health Organization (WHO) updated HIV management guidelines, was emphasized. The new guidelines suggest that the new HIV policy framework will help decision-makers optimize ongoing work and collaborations, advancing PHC and responses for specific disease groups, including elderly PLWH.
SGBCC  International Dialogue| Dr. Li Zhu & Dr. Giuseppe Curigliano Discuss the Need for Adjuvant Therapy After Achieving pCR in Neoadjuvant Treatment

SGBCC  International Dialogue| Dr. Li Zhu & Dr. Giuseppe Curigliano Discuss the Need for Adjuvant Therapy After Achieving pCR in Neoadjuvant Treatment

2024.01.14
Neoadjuvant therapy has become an integral part of breast cancer treatment, with its increasing application in clinical practice. However, improving the effectiveness of neoadjuvant therapy and optimizing subsequent treatment strategies is a complex issue to consider. At the 18th St.Gallen Breast Cancer Conference (SGBCC 2023), a debate titled "If you achieve pCR after neoadjuvant, do you need adjuvant therapy?" drew global expert attention. Oncology Frontier had  invited Dr. Li Zhu from Shanghai Jiao Tong University School of Medicine, First People's Hospital, and Dr. Giuseppe Curigliano from the University of Milan School of Medicine to engage in an in-depth discussion on this topic.
Dr. Jian Zhang Discusses with Dr. Harbeck: Is Chemotherapy Necessary for ER+/HER2- Breast Cancer Patients with Low Genetic Risk but High Clinical Risk

Dr. Jian Zhang Discusses with Dr. Harbeck: Is Chemotherapy Necessary for ER+/HER2- Breast Cancer Patients with Low Genetic Risk but High Clinical Risk

2024.01.14
The 18th St. Gallen International Breast Cancer Conference (SG-BCC 2023) was held in Vienna, the "City of Music," from March 15 to 18, 2023. Breast cancer experts from around the world gathered at this conference to discuss the most cutting-edge and controversial topics in the diagnosis and treatment of early-stage breast cancer, leading to the formation of the updated St. Gallen International Expert Consensus on Early Breast Cancer every two years. Oncology Frontier invited Dr. Jian Zhang from Fudan University Affiliated Cancer Hospital to have an in-depth discussion with Dr. Nadia Harbeck from the University of Munich on the topic of whether chemotherapy is needed for patients with low genetic risk but high clinical risk (ER+/HER2-) breast cancer.

CDL (co-management of diabetes-liver diseases strategy,) Literature Monthly Review – November 2023, Issue 10

2024.01.10
Diabetes and liver diseases are common chronic conditions in China, and they interact in terms of pathogenesis, clinical manifestations, and therapeutic targets, often posing mutual risk factors. Co-management of these conditions is beneficial for reducing the burden of disease. To support the development of diabetes and liver disease co-management in China, this publication Hepatology Digest, in collaboration with the co-management of diabetes-liver diseases strategy, (CDL), presents the CDL Literature Monthly Review column. Each month, we share research literature related to the mechanisms and therapeutic advances in diabetes combined with liver diseases. We invite experts in the field to comment on the literature, hoping to provide insights and assistance for professionals, researchers, and frontline medical workers engaged in scientific research and clinical diagnosis and treatment.

Efficacy Analysis of “T+A” Therapy in Different Treatment Populations of HCC

2024.01.08
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Most patients are unable to undergo surgical resection at the time of diagnosis, making systemic therapy an important treatment approach for this group. The combination immunotherapy of Atezolizumab plus Bevacizumab (“T+A”) has become the new first-line standard treatment for unresectable HCC patients due to its significant improvement in overall survival (OS) compared to sorafenib. However, its effectiveness in different populations, including HCC patients with different etiologies, Child-Pugh B grade HCC, and intermediate-stage HCC beyond the up-to-seven criteria, remains unclear. The journal "Hepatology Digest" has reviewed recent studies on this topic for the benefit of readers.
Dr. Huiguo Ding: AMMON-OHE Model for Risk Stratification of Outpatient Cirrhosis Patients for Overt Hepatic Encephalopathy

Dr. Huiguo Ding: AMMON-OHE Model for Risk Stratification of Outpatient Cirrhosis Patients for Overt Hepatic Encephalopathy

2023.12.25
The occurrence of overt hepatic encephalopathy (OHE) in cirrhosis patients leads to a decrease in their health-related quality of life, along with a significant increase in the risk of hospitalization and death. At the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023, Dr. María Pilar Ballester and her team from the Clinical Hospital of the University of Valencia in Spain introduced a new model for assessing the risk of OHE in outpatient cirrhosis patients - the AMMON-OHE model, which can effectively predict the risk of the first episode of OHE. Dr Huiguo Ding's team from Capital Medical University Affiliated Beijing You'an Hospital, invited by Hepatology Digest, reviewed this research for readers to learn and reference.
IDWeek Commentary | Dr. Hongzhou Lu: Can ” Online Celebrity Weight Loss Drugs” Also Be Used for HIV-Infected Individuals?

IDWeek Commentary | Dr. Hongzhou Lu: Can ” Online Celebrity Weight Loss Drugs” Also Be Used for HIV-Infected Individuals?

2023.12.10
Experiencing weight gain due to medication" is a common concern for many people living with HIV (PLWH). Some antiretroviral therapy (ART) regimens are associated with weight gain and related metabolic complications. In the field of endocrinology, newer antidiabetic medications like glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used for weight management and have gained popularity. So, are these new weight loss treatments suitable for PLWH experiencing ART-related weight gain? At the 2023 Infectious Diseases Week (IDWeek 2023), two studies on the use of GLP-1 RAs in PLWH and one study of weight control using protease inhibitor switching were presented. Dr. Hongzhou Lu from Shenzhen Third People's Hospital (The Second Hospital Affiliated with the School of Medicine, Southern University of Science and Technology) provides an introduction and commentary on these studies.
IDWeek Commentary | Dr. Yonghong Xiao: Intestinal colonization with MDRO, horizontal transmission and risk for bloodstream infection

IDWeek Commentary | Dr. Yonghong Xiao: Intestinal colonization with MDRO, horizontal transmission and risk for bloodstream infection

2023.11.30
Bacterial drug resistance is a significant challenge in the global public health field. Multidrug-resistant organisms (MDROs), represented by carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), and vancomycin-resistant Enterococcus (VRE), exhibit high resistance and rapid transmission. Previous studies have established a close relationship between intestinal CRE colonization and infection, but the relationship between intestinal colonization and infection of other MDROs remains to be clarified. In a recent oral presentation at the 2023 Infectious Diseases Week (IDWeek 2023), a researcher reported a study on the relationship between MDRO intestinal colonization and the risk of bloodstream infection (BSI). Dr. Yonghong Xiao, from the First Affiliated Hospital, Zhejiang University School of Medicine, provides an introduction and commentary on this research.
IDWeek Highlights |Dr. Yi-min Wang: Bundle Diagnosis for VAP Can Reduce Misdiagnosis and Antibiotic Overuse

IDWeek Highlights |Dr. Yi-min Wang: Bundle Diagnosis for VAP Can Reduce Misdiagnosis and Antibiotic Overuse

2023.11.27
Precision treatment starts with accurate diagnosis. The clinical diagnosis of ventilator-associated pneumonia (VAP) is challenging, with a high misdiagnosis rate leading to excessive antibiotic use. At the recent 2023 IDWeek conference in the United States, a clinical trial was reported that utilized a bundled approach to VAP diagnosis and management. The results showed that it is safe and significantly reduces the respiratory culture positivity rate and antibiotic usage. Below, Professor Wang Yimin and his team from the China-Japan Friendship Hospital introduce and comment on this study.